Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease
Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
This study was designed to test the hypothesis that the addition of full-dose atorvastatin
(80 mg/day) to conventional medical treatment could reduce ischaemic recurrences after
non-ST-elevation acute myocardial infarction (NSTE-AMI) in patients with severe and diffuse
coronary artery disease (CAD) not amenable to any form of mechanical revascularisation.
Phase:
Phase 3
Details
Lead Sponsor:
San Filippo Neri General Hospital
Collaborator:
Associazione Nazionale Medici Cardiologi Ospedalieri